Discovery Laboratories Inc. reaped more good news with Surfaxin, which met statistical significance in the co-primary endpoints of a pivotal Phase III trial in premature infants afflicted with respiratory distress syndrome. (BioWorld Today) Read More
BioWorld's offices will be closed Thursday, Nov. 27, and Friday, Nov. 28, in observance of the Thanksgiving holiday in the U.S. No issues will be published those days. The next issue of BioWorld Today will be published Monday, Dec. 1. Read More
